These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 7965968)

  • 21. RhD hemolytic disease of the newborn.
    Bowman JM
    N Engl J Med; 1998 Dec; 339(24):1775-7. PubMed ID: 9845715
    [No Abstract]   [Full Text] [Related]  

  • 22. Underreporting of mortality from RhD haemolytic disease in Scotland and its implications: retrospective review.
    Whitfield CR; Raafat A; Urbaniak SJ
    BMJ; 1997 Dec; 315(7121):1504-5. PubMed ID: 9420492
    [No Abstract]   [Full Text] [Related]  

  • 23. [Mechanism of action of anti-D-gamma globulin in preventing rhesus alloimmunization in the pregnant woman and hemolytic disease of the newborn infant].
    Vŭlcheva B; Spasova K
    Akush Ginekol (Sofiia); 1985; 24(2):73-6. PubMed ID: 2990248
    [No Abstract]   [Full Text] [Related]  

  • 24. Oliver memorial lecture. Towards the conquest of Rh haemolytic disease: Britain's contribution and the role of serendipity.
    Tovey LA
    Transfus Med; 1992 Jun; 2(2):99-109. PubMed ID: 1339195
    [No Abstract]   [Full Text] [Related]  

  • 25. Controversies in Rh prophylaxis.
    Hensleigh PA
    Am J Obstet Gynecol; 1985 Sep; 153(1):112-3. PubMed ID: 2994476
    [No Abstract]   [Full Text] [Related]  

  • 26. Consensus conference on anti-D prophylaxis, April 7 & 8, 1997: final consensus statement. Royal College of Physicians of Edinburgh/Royal College of Obstetricians and Gynaecologists.
    Urbaniak SJ
    Transfusion; 1998 Jan; 38(1):97-9. PubMed ID: 9482402
    [No Abstract]   [Full Text] [Related]  

  • 27. Haemolytic disease of the newborn.
    Whitfield CR; Lee D
    BMJ; 1990 Mar; 300(6727):814. PubMed ID: 2157515
    [No Abstract]   [Full Text] [Related]  

  • 28. Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn.
    Kumpel BM
    Clin Exp Immunol; 2008 Oct; 154(1):1-5. PubMed ID: 18727626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Causes and clinical consequences of Rhesus (D) haemolytic disease of the newborn: a study of a Scottish population, 1985-1990.
    Hughes RG; Craig JI; Murphy WG; Greer IA
    Br J Obstet Gynaecol; 1994 Apr; 101(4):297-300. PubMed ID: 8199074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prenatal immunoglobulin prevention in Rh(D)-negative nonsensitized pregnant women].
    Katsulov A
    Akush Ginekol (Sofiia); 1997; 36(2):1-2. PubMed ID: 9471891
    [No Abstract]   [Full Text] [Related]  

  • 31. The global burden of Rh disease.
    Zipursky A; Paul VK
    Arch Dis Child Fetal Neonatal Ed; 2011 Mar; 96(2):F84-5. PubMed ID: 21037283
    [No Abstract]   [Full Text] [Related]  

  • 32. [Rhesus prophylaxis--history and current status].
    Behrens O; Lellé RJ
    Zentralbl Gynakol; 1997; 119(5):204-10. PubMed ID: 9281253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The expediency of producing antirhesus-Rh0(D) immunoglobulin and its use for preventing hemolytic disease of the newborn (for discussion)].
    Mikhaĭlova AA; Klimova NIa
    Gematol Transfuziol; 1992; 37(7-8):39-40. PubMed ID: 1342987
    [No Abstract]   [Full Text] [Related]  

  • 34. Diagnosis and treatment of severe alloimmunization.
    Bennebroek Gravenhorst J
    Vox Sang; 1994; 67 Suppl 3():235-8. PubMed ID: 7975499
    [No Abstract]   [Full Text] [Related]  

  • 35. [Prevention of hemolytic disease of the fetus and the newborn: it is necessary to act].
    Mannessier L; Alie-Daram S; Roubinet F; Valat AS; Depoortère MH; Fournié A; Puech F
    J Gynecol Obstet Biol Reprod (Paris); 2000 Sep; 29(5):441-4. PubMed ID: 11011272
    [No Abstract]   [Full Text] [Related]  

  • 36. Preventing Rhesus D haemolytic disease of the newborn by giving anti-D immunoglobulin: are the guidelines being adequately followed?
    Howard HL; Martlew VJ; McFadyen IR; Clarke CA
    Br J Obstet Gynaecol; 1997 Jan; 104(1):37-41. PubMed ID: 8988694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The experience and effectiveness of the Nova Scotia Rh program, 1964-84.
    Baskett TF; Parsons ML; Peddle LJ
    CMAJ; 1986 Jun; 134(11):1259-61. PubMed ID: 3011235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparative analysis of the effects to date of the prevention of Rh incompatibility].
    Jedwabny A; Suchocki S; Bobrowska G
    Acta Haematol Pol; 1988; 19(1-2):56-8. PubMed ID: 2853507
    [No Abstract]   [Full Text] [Related]  

  • 39. [Prevention with anti-D gamma globulin at the Research Institute of Obstetrics and Gynecology].
    Spasova K; Vŭlcheva B
    Akush Ginekol (Sofiia); 1984; 23(6):500-4. PubMed ID: 6099699
    [No Abstract]   [Full Text] [Related]  

  • 40. Economics of antenatal prophylaxis.
    Cairns JA
    Br J Obstet Gynaecol; 1998 Nov; 105 Suppl 18():19-22. PubMed ID: 9863974
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.